Top 7 Semaglutide Companies Driving Innovation in Diabetes Care, Obesity Treatment, and Metabolic Health Solutions

Semaglutide is used to control obesity and treat type 2 diabetes. It mimics the hormone that controls blood sugar and hunger by acting as a GLP-1 receptor agonist. It is injected and aids in weight loss by lowering blood sugar levels. Semaglutide-based treatments are becoming more widely accepted as they encourage weight loss, enhance glycemic management, and are used in a larger range of patient populations. Rising incidence of chronic conditions such as Type 2 diabetes and obesity, growing consciousness of semaglutide’s advantages in controlling blood sugar and weight, and government programs to enhance healthcare outcomes and access are bolstering industry expansion.

The integration of digital health technologies, including telemedicine platforms and mobile health applications, is transforming patient care by improving treatment adherence, engagement, and real-time health monitoring. This evolution reflects a broader shift toward holistic healthcare models, where pharmaceutical therapies are complemented by digital tools, personalized support, and preventive care strategies to enhance overall patient outcomes.

According to a report by Fortune Business Insights™, the market for semaglutide reached USD 34.52 billion in 2025 and is predicted to reach USD 86.05 billion by 2034 with a CAGR of 10.27% from 2026 to 2034.

Fortune Business Insights™ Profiles Top 7 Semaglutide Companies in the  Market

1. Novo Nordisk A/S

First-up in the list of top 7 semaglutide companies is Novo Nordisk A/S. It is a Denmark-based healthcare company with over 95 years of innovation and leadership in diabetes care,  concentrating on creating research-based solutions to defeat serious chronic diseases and create long-term health. The company is assisting people in their weight-loss and health journeys. Novo Nordisk A/S excels in the creation and marketing of pharmaceutical products. It emphasizes diabetes care and provides insulin delivery systems.

• March 2026: Novo Nordisk declared a more than USD 451.47 million investment for its Athlone facility. This investment marked a stronger production infrastructure to assist the future supply chain of obesity and diabetes therapies and decrease capacity-related growth restraints.

2. Sun Pharmaceutical Industries Limited

Founded in 1983, Sun Pharmaceutical Industries Limited is an Indian pharmaceutical company and a renowned player in specialty medicines. It produces and sells pharmaceuticals for domestic and international distribution. It has different types of dosage forms such as sprays, ointments, creams, injectables, liquids, tablets, and capsules. It tries to improve access to medicines and enhance patient care, generating better health outcomes for millions across the globe.

• July 2025: Sun Pharmaceutical Industries Limited introduced LEQSELVI 8 mg tablets in the U.S., presenting a fast-acting treatment option for adult patients with severe alopecia areata maintained by strong clinical trial results.

3. Zydus Lifesciences Limited

Headquartered in India, Zydus Lifesciences Limited is one of the top 7 semaglutide companies, offering excellent service & high-quality generics. It has production capacities across the complete pharmaceutical value chain such as APIs, vaccines, biosimilars, formulations, complex products, and wellness products. The company is engaged in the discovery, production, and marketing of healthcare therapies. Its portfolio comprises finished dosage human formulations, branded generics, and specialty formulations. Its products find application in the therapeutic areas of cardiovascular, respiratory, pain management, gastrointestinal, cancer, inflammation, neurology, and women's health.

• In May 2025, Zydus Lifesciences unveiled a single-pen Semaglutide treatment for diabetes and obesity. This advanced device lets patients choose from multiple dose strengths in one pen, enhancing convenience and adherence.

4. NATCO Pharma Limited

Founded in 1981, NATCO Pharma Limited is an eminent Indian innovative and quality pharmaceutical solution company. It emphasizes holistic expansion, solid governance, and nurturing community and ecological prosperity. NATCO Pharma Limited sells its products in more than 50 countries. It specializes in production niche and intricate pharmaceutical and crop health science products, fulfilling demands with precision and care. This vertically integrated pharmaceutical company offers Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).

• March 2026: NATCO Pharma Limited teamed up with Breckenridge Pharmaceutical, Inc. and declared the introduction of Pomalidomide Capsules in the U.S. The product is a generic version of Pomalyst®, originally created by Celgene.

5. Eris Lifesciences Limited

Based in India, Eris Lifesciences Limited concentrates on enhancing pharmaceutical solutions in dedicated therapeutic areas. Its approach is based on offering science-led and outcome-driven healthcare, with a primary emphasis on specialty and super-specialty medical treatments. Its key product areas comprise therapies for cardiovascular diseases, vitamins, dermatology, insulins, oral anti-diabetes, women's health, critical care, and oncology. It creates pharmaceutical formulations to treat chronic and sub-chronic diseases. The company's products contain sprays, syrups, drops, powder, injections, tablets, capsules, cookies, ointments and soft gels to treat pain, diabetes, neuroscience, cardiovascular, respiratory, and gastrointestinal disorders. It sells its products under brands such as Carpela, Citelec, DeepSenz, Obicure, Glimisave, Alerfix, Atorsave F, and Axunil.

6. Hangzhou Jiuyuan Gene Engineering Co., Ltd.

Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a Chinese company that creates and distributes biochemical and chemical pharmaceuticals and other medical equipment. The company offers chemical drugs, bacterial and virus vaccines, and toxoids. Its therapeutic services comprise metabolic diseases, oncology, orthopedics, and hematology services.  It excels in R&D, production, and commercialization of biopharmaceutical products and medical devices. Its drug pipeline mainly contains Fosaprepitant, Pegfilgrastim, Liraglutide, Fulvestrant, and other high-value biosimilars.

7. Sandoz AG

Founded in 1886, Sandoz AG is a Switzerland-based generics and biosimilars company that creates more affordable versions of high-quality medicines. Its product range includes around 1,300 quality generic and biosimilar medicines. It also offers intermediary products such as Active Pharmaceutical Ingredients (APIs), and biotechnology manufacturing services to other companies. It delivers active ingredients and finished dosage forms of pharmaceuticals across dermatology, respiratory, metabolism, central nervous system, cancer, cardiovascular, pain, and hormonal therapies.

Growing Health Burden of Type 2 Diabetes and Obesity is Sparking Semaglutide Boom

The increasing prevalence of type 2 diabetes and obesity across the globe bolsters the demand for semaglutide, which is well-known for its efficiency in controlling weight and blood sugar levels. More people are being diagnosed with metabolic diseases that call for efficient therapeutic interventions as sedentary lifestyles and bad eating habits become more common. Patients with these chronic illnesses find semaglutide to be an appealing therapeutic choice due to the dual benefits of lowering blood sugar levels and promoting significant weight loss it offers. More than 650 million adults are estimated to be obese, according to the World Health Organization (WHO), indicating that the number of people diagnosed with obesity has reached concerning levels. Type 2 diabetes, which affects over 462 million people globally, is intimately related to this illness. Additionally, the number of patients seeking cutting-edge pharmaceutical solutions has increased as a result of public health campaigns and heightened awareness of problems such as diabetes and obesity.